Increasing the Sensitivity of Genomic Assays Permits a Higher Resolution Study of the Human Genome. Our Current Knowledge of Genetics and Genomics
|
|
- Marcia O’Neal’
- 5 years ago
- Views:
Transcription
1 Our Current Knowledge of Genetics and Genomics Unlocking the Diagnostic Potential of Genomic Medicine The Beaumont DNA Array Experience Mark Micale, Ph.D., F.A.C.M.G. Medical Director, Clinical Cytogenomics Laboratory Department of Pathology and Laboratory Medicine Beaumont Health System Associate Professor of Pathology and Laboratory Medicine Oakland University William Beaumont School of Medicine The Anatomy Lesson of Dr. Nicolaes Tulp Rembrandt 1632 Karyotyping Has Been the Gold Standard for Identifying Chromosome Abnormalities The era of modern cytogenetics began in 1956 with the discovery by Tijo and Levan that the human diploid chromosome number was 46 In 1959, Lejeune reported on the chromosomal basis of Down syndrome In 1960, Nowell and Hungerford demonstrated an association between chromosomes and cancer with the discovery of the Philadelphia chromosome in chronic myeloid leukemia : Additional associations between chromosome abnormalities and specific phenotypes were made (Turner, Klinefelter, Cri-duchat, Patau, Edward, Bloom, Fanconi anemia) Conventional cytogenetics (karyotyping) represents a whole-genome test but has somewhat limited resolution (5-10Mb) Karyotyping is great at identifying larger chromosome abnormalities, but is not good at identifying smaller rearrangements associated with intellectual disability, multiple congenital anomalies, and autism/asd Molecular Cytogenetics (FISH) Provides High-Resolution Targeted Genomic Analysis FISH was introduced into the clinical lab in the late 80s, and prenatal FISH aneuploidy detection became routine in the mid 1990s FISH is far more sensitive than karyotyping, but only interrogates a specific genomic region of interest FISH is a great test in those clinical settings whereby the phenotype provides some differential diagnosis: - Common microdeletion/microduplications syndromes - Fetal chromosome aneuploidy - FISH panels for hematolymphoid disorders; detection of specific rearrangements in AML, CML, etc. Resolution of Conventional and FISH Chromosome Analysis Increasing the Sensitivity of Genomic Assays Permits a Higher Resolution Study of the Human Genome Resolution Coverage Karyotyping >5-10Mb Complete FISH (interphase) >20kb Probe specific FISH (metaphase) >100kb Probe specific Chromosome 50kb/SNP 1 bp Complete microarray/single nucleotide polymorphism (SNP) array analysis Chromosome Microarray (CMA) or Single Nucleotide Polymorphism (SNP) Analysis Other highly-sensitive molecular assays: Massively parallel sequencing, exome or whole-genome sequencing (NextGen sequencing), mutation detection 1
2 Chromosome Microarray Analysis (CMA) Molecular Karyotyping A Normal CMA Study Analyzes multiple genetic loci at higher resolution than available by conventional cytogenetics (100kb vs. 5-10Mb) Compares DNA content between two differentially labeled chromosomes patient and reference DNA CMA Results - Characterization of Chromosome 18q21.2 Deletion CMA in the Diagnosis of Constitutional Genetic Syndromes DiGeorge Syndrome 2.47 Mb 22q11.2 deletion Prader Willi/Angelman Syndrome 5.81Mb 15q11.2q13.1 deletion 18q Mb deletion 73 probes 10 genes Potocki-Lupski Syndrome 3.39Mb 17p11.2 duplication My Very Own CMA Abnormality - Chromosome 18q23 Duplication CMA Sensitivity is Based on Array Element Distribution 18q23 copy gain ~210.51kb duplication 24 probes 2 genes CTDP1 gene KCNG2 gene 2
3 CMA Characterization of 2.4Mb Chromosome 10 Deletion [del(10)(q25.1q25.1)] Low-resolution array High-resolution array Aston E et al (2008): J Med Genet 45, SCIENCE 305(23): JULY 2004, 525 Copy Number Variants (CNVs) Genomic deletions or duplications that may represent rare or common benign variants or pathologic variants (1kb - several Mb in size) May encompass as much as 12% of the genome CNV may be clinically significant in child but have no phenotype in carrier parent - Addl environmental an genomic factors needed - CNV may be variably penetrant By constructing arrays that eliminate highly variable regions, frequency of benign variants can be minimized Currently more of a problem with oligo arrays Most resolved by parental studies Databases are needed for proper interpretation of CNVs Proprietary, Open access Database of Genomic Variants This is a problem for prenatal CMA Is a CNV Benign or Pathogenic? Size Location Genomic content Comparison with other cases Inherited or de novo Example of a Benign CNV Is a CNV Benign or Pathogenic? Benign kb chromosome 9p23 deletion. Notice that there are no genes in the deleted region. Miller DT et al (2010), AJHG 86,
4 CMA Has Been Transformational to the Practice of Clinical Genetics Child presents with developmental delay and microcephaly Am J Hum Genet 86, , Genet Med 12(11), 2010 CMA Identifies Three Genomic Abnormalities Resulting in Gain of 50 Genes 42.95kb Chromosome 22q Deletion Involving the SHANK3 Gene Derivative chromosome 4 with a 2.15 Mb single copy gain involving chromosome 4q21.23 with the likely formation of a neocentromere Derivative chromosome 8 with a 5.91 Mb single copy gain involving 8p q11.1 as well as a kb two copy gain within that segment (band 8p11.21). Derivative X chromosome with (a) a single copy gain of a 1.28 Mb segment involving Xp11.22 (HSD17B10, HUWE1, and PHF8 genes all associated with intellectual disability) and (b) a single copy gain of a 5.07Mb segment involving the pericentromeric region of the X chromosome Seven year old referred for developmental delay, ADHD, and speech apraxia 42.95kb deletion identified that knocks out one gene- SHANK3 This defines the Phelan- McDermid (22q13.3 microdeletion) syndrome; the deletion explains the child s phenotype Identification provides accurate genetic counseling and accurate risk assessment in future pregnancies CMA identifies a chromosome 3p triplication in a child with developmental delay CMA has Identified Novel Microdeletion/Microduplication Syndromes Ballif BC et al (2007): Discovery of a previously unrecognized microdeletion syndrome of 16p11.2-p12.1. Nat Genet 39(9), Shaffer LG et al (2007): The discovery of microdeletion syndromes in the post-genomic era: review of the methodology and characterization of a new 1q41q42 microdeletion syndrome. Genet Med 9(9),
5 CMA studies on children with developmental delay, mental retardation, and multiple congenital anomalies Beaumont Constitutional CMA Experience Reported diagnostic yield of CMA is 8-17% depending on methodology and selected patient population; most of these patients had a normal karyotype. Number of studies performed: Number of cases with one or more clinically significant abnormalities: 330 (October 2009-present) 74 (22.4% yield) CMA detects de novo CNVs in 10% of patient s with autism (16p11.2 autism locus). CMA identifies more microdeletions than microduplications (may be technical or patient selection bias due to milder phenotype in duplications) Determination of the clinical significance of CNVs remains an issue Smallest imbalance: kb (SHANK3 gene - Phelan McDermid Syndrome) Largest Imbalance: 32.8 Mb (Cri-du-Chat syndrome) 16p deletion/duplication: 6/74 cases 8p inverted duplication/deletion syndrome: 4/74 cases Rare genetic syndromes identified: Pitt-Hopkins syndrome (535kb) Opitz/GBBB syndrome (140.58kb) Number of cases with abnormality(s) of uncertain clinical significance: 54 (16.4%) Prenatal Cytogenetic Analysis Conventional karyotyping detects chromosome abnormalities in: - 35% of pregnancies with fetal ultrasound abnormalities (All) - 2-3% of pregnancies presumed to be at-risk - 40% of prenatally ascertained heart defects (22q11.2 FISH) - 50% of pregnancies with cystic hygroma % of pregnancies with omphalocele - >50% with nasal bone absence - 40% of pregnancies with nuchal fold (2 nd trimester) The clinical sensitivity of prenatal interphase FISH (for rapid aneuploidy detection) in the AMA population approaches 80%, but falls to 65-70% for all prenatal patients Classical cytogenetics (karyotyping) is not good at detecting small (<5Mb) deletions or duplications that may be clinically significant. FISH is great at detecting such imbalance, but only if there are clinical cues to guide appropriate choice of DNA probe used But what about a fetus with U/S anomalies and a normal karyotype? Will Prenatal Array Replace the Karyotype? NICHD study of 4,450 unselected prenatal cases from 29 centers (4 reference labs) - Normal karyotype with U/S anomalies: addl. 6.0% of cases - AMA: 1.7% - Screen positive: 1.6% - Variants of uncertain clinical significance (VOUS): 1.5% Emory University (ISCA Consortium) Experience - Normal karyotype with U/S anomalies (n=755): addl. 6.0% of cases - AMA (n=1,966): 1.7% - Screen positive (n=729): 1.7% - VOUS: 1.6% LabCorp Experience (>1,600 specimens) - 6.1% pathogenetic CNVs identified - 3.0% consanguinity, 3.6% UPD - VOUS: 1.3% Signature Genomic Laboratories - Normal karyotype with U/S anomalies: addl. 6.6% of cases - AMA: 0.3% - Screen positive: 5.2% - VOUS: 1.0% when accounting for parental inheritance Normal Karyotype With Abnormal CMA Result Utility of Prenatal Array in Pregnancies With Ultrasound Anomalies Amniocentesis for ventriculomegaly and agenesis of the corpus callosum 46,XX CMA done on 9 week old child for multiple congenital anomalies, ACC, and lack of normal development 2.88Mb chromosome 1q44 deletion which includes the 1qter critical region for corpus callosum agenesis/hypogenesis LabCorp (n=>1600) Signature Genomics (n=3,876) U/S Finding Positive Findings U/S Finding Positive Findings Single abn. 5.6% Single abn. 5.6% Multiple abns. 15.3% Multiple abns. 9.8% Brain 9.6% Abn. Of growth 2.6% Kidney 10.9% > One soft sign 2.6% Cardiac 6.8% Holoprosencephaly 11% Posterior fossa defect 14.6% Skeletal anomalies 10.8% VSD 11.4% Hypoplastic left heart 16.2% Based on these studies, ACOG will likely recommend that array should be used as a first-tier test in certain prenatal clinical situations 5
6 Considerations in Prenatal CMA Analysis Applications of SNP Array Analysis in Oncology The parental anxiety created by identifying CNVs of unknown significance The need to do parental CMA studies to further characterize uncertain results Familial variants are not always benign due to reduced penetrance and variable expressivity The need for pretest and posttest genetic counseling The identification of a genomic imbalance that is not related to the reason for referral nor to the observed phenotype, but rather to late-onset disorders, infertility, neurological, or cancer predisposition loci Will (and should) CMA replace standard karyotyping and FISH, and when? Chronic lymphocytic leukemia Myelodysplastic syndrome Plasma cell myeloma Acute lymphoblastic leukemia Acute myeloid leukemia Renal cell carcinoma Meduloblastoma Glial tumors Neuroblastoma SNP Oligonucleotide Arrays SNP arrays identify a set of genetic variants (single nucleotide polymorphisms) in an individual; Estimated one SNP/ bp Probes on a SNP array consist of oligonucleotides that contain SNPs; SNP arrays can distinguish parental alleles at heterozygous loci 9.2 million SNPs have been reported (HapMap); 300, ,000 SNPs contain most of the information about the patterns of genetic variation SNP genotyping permits genome-wide high-resolution detection of copycopy number changes (Affymetrix CytoHD SNP array with million DNA markers) SNP Arrays Detect Copy Number Neutral Loss of Heterozygosity (aupd) A B A A SNP C T C C Mitotic Recombination Error Resulting in Segmental UPD UPD has been described in CLL, PCV leading to JAK2 homozygosity, MDS/MPD, AML, and follicular lymphoma Principles of Copy Number Detection and Genotyping Using SNP Arrays The Power of SNP Array Analysis A Case of Mantle Cell Lymphoma Sato-Otsubo A et al (2012): Sem Oncol 39(1). The problem with current SNP arrays is that they can t detect balanced rearrangements! Normal karyotype Positive for IGH/CCND1 fusion and for monosomy 13 by FISH 6
7 The Power of SNP Array Analysis A Case of Mantle Cell Lymphoma The Power of SNP Array Analysis A Case of Mantle Cell Lymphoma UPD (CNNLOH) 4 or more copies Normal disomy Deletion * RB1 gene LAMP1 gene * FISH misidentified this as monosomy 13. In fact, it s far more complicated! SNP Array Analysis of Chronic Lymphocytic Leukemia CLL is a highly variable disease with life expectancies from a few months to many decades CLL FISH panel detects abnormalities that may not be found by karyotype CLL SNP array useful as the disease is characterized by genomic gain or loss CLL SNP array has high concordance with other studies; however, SNP array can identify 30-76% more abnormalities Elevated CLL genomic complexity is an independent and powerful marker to identify patients with aggressive disease and a shorter survival! SNP Array Analysis in AML Copy number alterations are identified in 15-40% of AML patients with a normal karyotype and predict an adverse clinical outcome Yi et al, 2011 The implementation of SNP array analysis in AML can increase the detection of clinically significant anomalies (including aupd) from ~50% by karyotyping to ~87% Copy number alterations were identified in 40-90% of MDS/AML patients with abnormal clones and nearly 100% of cases with complex karyotypes Hagenkord JM (2010) SNP Array Analysis in Renal Cell Carcinoma Clear cell RCC Papillary RCC Mucinous, tubular, and spindle cell carcinoma Chromophobe RCC Oncocytoma The Significance of Acquired UPD as Detected by SNP Array Analysis Copy neutral LOH is known to constitute between 50-80% of LOH in all human cancers aupds are found in: - 20% of AML - 30% of MDS - 80% of lymphomas O Shea et al (2009): Regions of aupd at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 113(10). UPDs are associated with homozygous mutations of a number of tumor suppressor genes including TET2, CDKN2A/B, TP53, NF1, Rb, CEBPa, and RUNX1 UPDs are also associated with gain-of-function alleles of oncogenes including JAK2, NRAS, c-cbl, and FLT3 7
8 SNP Molecular Karyotyping in Neuroblastoma SNP Molecular Karyotyping in Neuroblastoma Neuroblastoma (NB), the most common extracranial tumor of childhood, can vary in clinical behavior from highly aggressive to spontaneous regression. Children <1 year present with localized tumor and have an excellent outcome while older children have more aggressive disease and a poorer prognosis. The prognosis is highly dependent on cytogenetic characterization: Good Prognosis Poor Prognosis Near-triploidy Near-diploidy or near-tetraploidy Numerical only with segmental rearrangements MYCN gene amplification Genome-wide microarray analysis is an excellent tool to assess cytogenetic status and is important to fully evaluate risk, aid diagnosis, and guide treatment del(11q) NBs constitute a unique group of unfavorable tumors with distinct features that differ from the other high-risk NB group (MYCN-amplified) Caren et al (2010): PNAS 107(9) Caren et al (2010): PNAS 107(9) Other Molecular Technologies May Supplant CMA The $1000 Genome Will Transform Medicine (and Make it a Lot More Complicated!) Ion Torrent Proton Sequencer Thank You 8
Whole-Genome SNP Array Analysis Genomic Complexity and Clinical Relevance in Prenatal, Postnatal, and Oncology Testing
The Evolution of Cytogenetics Testing Whole-Genome SNP Array Analysis Genomic Complexity and Clinical Relevance in Prenatal, Postnatal, and Oncology Testing Mark Micale, Ph.D., F.A.C.M.G. Medical Director,
More informationCHROMOSOMAL MICROARRAY (CGH+SNP)
Chromosome imbalances are a significant cause of developmental delay, mental retardation, autism spectrum disorders, dysmorphic features and/or birth defects. The imbalance of genetic material may be due
More informationAddressing the challenges of genomic characterization of hematologic malignancies using microarrays
Addressing the challenges of genomic characterization of hematologic malignancies using microarrays Sarah South, PhD, FACMG Medical Director, ARUP Laboratories Department of Pediatrics and Pathology University
More informationClinical Cytogenomics Laboratory. Laboratory. Leading diagnostics for better medicine. Beaumont
Clinical Cytogenomics Laboratory Leading diagnostics for better medicine Beaumont Laboratory Beaumont Laboratory s Clinical Cytogenomics Lab Genome decoding is essential Knowledge of variations in genome
More informationApplications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns
Applications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns جواد کریمزاد حق PhD of Medical Genetics آزمايشگاه پاتوبيولوژي و ژنتيك پارسه
More informationChallenges of CGH array testing in children with developmental delay. Dr Sally Davies 17 th September 2014
Challenges of CGH array testing in children with developmental delay Dr Sally Davies 17 th September 2014 CGH array What is CGH array? Understanding the test Benefits Results to expect Consent issues Ethical
More informationSNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.
SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: LOSS,
More informationApplication of Whole Genome Microarrays in Cancer: You should be doing this test!!
Application of Whole Genome Microarrays in Cancer: You should be doing this test!! Daynna Wolff, Ph.D. Director, Cytogenetics and Genomics Disclosures Clinical Laboratory Director and Employee, Medical
More informationFaravareh Khordadpoor (PhD in molecular genetics) 1- Tehran Medical Genetics Laboratory 2- Science and research branch, Islamic Azad University
Faravareh Khordadpoor (PhD in molecular genetics) 1- Tehran Medical Genetics Laboratory 2- Science and research branch, Islamic Azad University 1395 21 مشاوره ژنتیک و نقش آن در پیش گیری از معلولیت ها 20
More informationClinical evaluation of microarray data
Clinical evaluation of microarray data David Amor 19 th June 2011 Single base change Microarrays 3-4Mb What is a microarray? Up to 10 6 bits of Information!! Highly multiplexed FISH hybridisations. Microarray
More informationClinical Genomics. Ina E. Amarillo, PhD FACMGG
Clinical Genomics Ina E. Amarillo, PhD FACMGG Associate Medical Director, Cytogenetics Lab (CaTG), Lab and Genomic Medicine Assistant Professor, Pathology and Immunology Outline Clinical Genomics Testing
More informationPrenatal Diagnosis: Are There Microarrays in Your Future?
Financial Disclosure UCSF Antepartum Intrapartum Management Course June 8 I have no financial relationship with any aspect of private industry Prenatal Diagnosis: Are There Microarrays in Your Future?
More informationSNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.
SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: GAIN,
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationAssociation for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology
Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology 9650 Rockville Pike, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7990 Email:
More informationMultiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016
Multiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016 Marwan Tayeh, PhD, FACMG Director, MMGL Molecular Genetics Assistant Professor of Pediatrics Department of Pediatrics
More informationApproach to Mental Retardation and Developmental Delay. SR Ghaffari MSc MD PhD
Approach to Mental Retardation and Developmental Delay SR Ghaffari MSc MD PhD Introduction Objectives Definition of MR and DD Classification Epidemiology (prevalence, recurrence risk, ) Etiology Importance
More informationGenetic Testing for Single-Gene and Multifactorial Conditions
Clinical Appropriateness Guidelines Genetic Testing for Single-Gene and Multifactorial Conditions EFFECTIVE DECEMBER 1, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2069-1217 Table of Contents
More informationPractical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs
Practical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs Joris Vermeesch, Center for Human Genetics K.U.Leuven, Belgium ESHG June 11, 2010 When and
More informationSharan Goobie, MD, MSc, FRCPC
Sharan Goobie, MD, MSc, FRCPC Chromosome testing in 2014 Presenter Disclosure: Sharan Goobie has no potential for conflict of interest with this presentation Objectives Review of standard genetic investigations
More informationGenetic Testing 101: Interpreting the Chromosomes
Genetic Testing 101: Interpreting the Chromosomes Kristin Lindstrom, MD Division of Genetics and Metabolism Phoenix Children s Hospital AzAAP Pediatrics in the Red Rocks I have no disclosures for this
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Single Nucleotide Polymorphism (SNP) Chromosomal Microarray Analysis for Prenatal Testing and Intellectual Disability, Developmental Delay, and Multiple
More informationClinical Interpretation of Cancer Genomes
IGENZ Ltd, Auckland, New Zealand Clinical Interpretation of Cancer Genomes Dr Amanda Dixon-McIver www.igenz.co.nz 1992 Slovenia and Croatia gain independence USA and Russia declare the Cold War over Steffi
More informationCHROMOSOME MICROARRAY TESTING
CHROMOSOME MICROARRAY TESTING UnitedHealthcare Commercial Medical Policy Policy Number: 2017T0559J Effective Date: August 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationCYTOGENETICS Dr. Mary Ann Perle
CYTOGENETICS Dr. Mary Ann Perle I) Mitosis and metaphase chromosomes A) Chromosomes are most fully condensed and clearly distinguishable during mitosis. B) Mitosis (M phase) takes 1 to 2 hrs and is divided
More informationMedical Policy. MP Invasive Prenatal (Fetal) Diagnostic Testing
Medical Policy MP 2.04.116 BCBSA Ref. Policy: 2.04.116 Last Review: 04/30/2018 Effective Date: 04/30/2018 Section: Medicine Related Policies 2.04.59 Genetic Testing for Developmental Delay/Intellectual
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationUnderstanding the Human Karyotype Colleen Jackson Cook, Ph.D.
Understanding the Human Karyotype Colleen Jackson Cook, Ph.D. SUPPLEMENTAL READING Nussbaum, RL, McInnes, RR, and Willard HF (2007) Thompson and Thompson Genetics in Medicine, 7th edition. Saunders: Philadelphia.
More informationSection: Medicine Effective Date: January15, 2016 Subsection: Pathology/Laboratory Original Policy Date: December 7, 2011 Subject:
Section: Medicine Effective Date: January15, 2016 Last Review Status/Date: December 2015 Page: 1 of 22 Microarray Analysis and Next-Generation Autism Spectrum Disorder and/or Congenital Description Chromosomal
More informationGenetic Testing for the Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
Genetic Testing for the Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies Policy Number: 2.04.59 Last Review: 5/2018 Origination: 5/2015 Next Review: 5/2019
More informationChromosome microarray analysis in routine prenatal diagnosis practice: a prospective study on 3000 consecutive clinical cases
Chromosome microarray analysis in routine prenatal diagnosis practice: a prospective study on 3000 consecutive clinical cases Fiorentino F, Napoletano S, Caiazzo F, Sessa M, Bono S, Spizzichino L, Gordon
More informationIntegration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
/, Vol. 6, No. 22 Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? Jess F. Peterson 1,2,6, Nidhi Aggarwal 3, Clayton
More informationHuman Genetic Variation Copy Number Variation
The Evolution of Laboratory Prenatal Diagnosis Lawrence D. Platt, MD Professor of Obstetrics and Gynecology David Geffen School of Medicine at UCLA Center for Fetal Medicine & Women s Ultrasound Los Angeles,
More informationThe role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia
The role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia Adrian Zordan, Meaghan Wall, Ruth MacKinnon, Pina D Achille & Lynda Campbell Victorian Cancer Cytogenetics Service (VCCS)
More informationCanadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010
Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination May 4, 2010 Examination Length = 3 hours Total Marks = 100 (7 questions) Total Pages = 8 (including cover sheet and 2 pages of prints)
More informationCorporate Medical Policy
Corporate Medical Policy Invasive Prenatal (Fetal) Diagnostic Testing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: invasive_prenatal_(fetal)_diagnostic_testing 12/2014 3/2018
More informationWhat s the Human Genome Project Got to Do with Developmental Disabilities?
What s the Human Genome Project Got to Do with Developmental Disabilities? Disclosures Neither speaker has anything to disclose. Phase Two: Interpretation Officially started in October 1990 Goals of the
More informationCNV Detection and Interpretation in Genomic Data
CNV Detection and Interpretation in Genomic Data Benjamin W. Darbro, M.D., Ph.D. Assistant Professor of Pediatrics Director of the Shivanand R. Patil Cytogenetics and Molecular Laboratory Overview What
More informationCHROMOSOME MICROARRAY TESTING (NON-ONCOLOGY CONDITIONS)
CHROMOSOME MICROARRAY TESTING (NON-ONCOLOGY CONDITIONS) UnitedHealthcare Oxford Clinical Policy Policy Number: LABORATORY 016.12 T2 Effective Date: June 1, 2018 Table of Contents Page INSTRUCTIONS FOR
More informationCopy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory
Copy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory http://www.nbt.nhs.uk/genetics Microarray CGH in Prenatal
More informationProtocol. Genetic Testing for Developmental Delay and Autism Spectrum Disorder
Genetic Testing for Developmental Delay and Autism Spectrum (20459, 20483, 20481) Medical Benefit Effective Date: 01/01/18 Next Review Date: 09/18 Preauthorization Yes Review Dates: 09/10, 09/11, 03/12,
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationreview Genetics IN Medicine 13
January 2008 Vol. 10 No. 1 review Pre- and postnatal genetic testing by array-comparative genomic hybridization: genetic counseling perspectives Sandra Darilek, MS, Patricia Ward, MS, Amber Pursley, MS,
More informationGenetics update and implications for (General) Practice
Genetics update and implications for (General) Practice May 12 th 2018 Women s Health Symposium Clearwater Estate Dr Kate Gibson MB BCh, MRCP, FRACP Topics NZ Clinical Genetics delivery New Technologies
More informationUTILIZATION OF A SNP MICROARRAY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: EFFICACY, INFORMATIVE FINDINGS AND PROGNOSTIC CAPABILITIES
UTILIZATION OF A SNP MICROARRAY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: EFFICACY, INFORMATIVE FINDINGS AND PROGNOSTIC CAPABILITIES S Schwartz, Z Hosseini, S Schepis, P Papenhausen Laboratory Corporation of America
More informationChromosome Microarray Analysis (CMA)
Chromosome Microarray Analysis (CMA) Ina E. Amarillo, PhD FACMG Cytogenomics Lab (Associate Medical Director) Pathology (Assistant Professor) OUTLINE Clinical Indications for Cytogenomics Testing Cytogenomics
More informationClinical Cytogenetic Testing: Applications in Constitutional and Oncology Settings Erica Andersen, PhD, FACMG
Clinical Cytogenetic Testing: Applications in Constitutional and Oncology Settings Erica Andersen, PhD, FACMG Medical Director, Cytogenetics and Genomic Microarray ARUP Laboratories Assistant Professor,
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): April 26, 2011 Most Recent Review Date (Revised): January 28, 2014 Effective Date: June 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationKaryology. Preparation and study of karyotypes is part of Cytogenetics.
Chromosomal Karyotyping Karyology Karyotyping - process of pairing and ordering all chromosomes of an organism, thus providing a genome-wide snapshot of an individual's chromosomes. Karyotypes describe
More informationBio 100 Guide 08.
Bio 100 Guide 08 http://images.andrewsmcmeel.com/media/3820/medium.jpg http://www.biology.iupui.edu/biocourses/n100/images/11nondisjunction.gif http://www.unm.edu/~vscience/images/hela%20karyotype%203%20(1000x).jpg
More informationClinical Policy Title: Array comparative genomic hybridization testing
Clinical Policy Title: Array comparative genomic hybridization testing Clinical Policy Number: 02.01.03 Policy contains: Chromosomal microarray analysis. Effective Date: September 1, 2015 Comparative genomic
More informationRACP Congress 2017 Genetics of Intellectual Disability and Autism: Past Present and Future 9 th May 2017
RACP Congress 2017 Genetics of Intellectual Disability and Autism: Past Present and Future 9 th May 2017 Why causation? Explanation for family Prognosis Recurrence risk and reproductive options Guide medical
More informationBio 105 Guide 08.
Bio 105 Guide 08 http://images.andrewsmcmeel.com/media/3820/medium.jpg The chromosomes present in 1 cell nucleus! http://www.unm.edu/~vscience/images/hela%20karyotype%203%20(1000x).jpg karyotype http://www.ucl.ac.uk/~ucbhjow/medicine/images/human_karyotype.gif
More informationscfish: A Primer Peter K. Rogan, Ph.D. Joan H. M. Knoll, Ph.D., FACMG, FCCMG Children s Mercy Hospitals and Clinics Tuesday, July 29, 2003
scfish: A Primer Peter K. Rogan, Ph.D. Joan H. M. Knoll, Ph.D., FACMG, FCCMG Children s Mercy Hospitals and Clinics Tuesday, July 29, 2003 FISH: A Molecular Cytogenetic Test Complementary nucleic acid
More informationInvasive Prenatal (Fetal) Diagnostic Testing
Protocol Invasive Prenatal (Fetal) Diagnostic Testing (204116) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 01/15, 01/16, 01/17, 01/18 Preauthorization
More informationNew and Developing Technologies for Genetic Diagnostics National Genetics Reference Laboratory (Wessex) Salisbury, UK - July 2010 BACs on Beads
New and Developing Technologies for Genetic Diagnostics National Genetics Reference Laboratory (Wessex) Salisbury, UK - July 2010 BACs on Beads Susan Gross, MD Division of Reproductive Genetics Professor
More informationClinical Policy Title: Array comparative genomic hybridization testing
Clinical Policy Title: Array comparative genomic hybridization testing Clinical Policy Number: 02.01.03 Effective Date: Sept 1, 2015 Initial Review Date: May 13, 2013 Most Recent Review Date: September
More informationNEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM. Crosswalk of Proposed Revisions to Cytogenetics Standards
2014 Standard 2014 Guidance 2016 Standard 2016 Guidance Cytogenetics Standard 1 (CG S1) The laboratory shall request clinical information necessary for proper initiation of test procedures and interpretation
More informationGenetic Counselling in relation to genetic testing
Genetic Counselling in relation to genetic testing Dr Julie Vogt Consultant Geneticist West Midlands Regional Genetics Service September 2016 Disclosures for Research Support/P.I. Employee Consultant Major
More informationImplementation of the DDD/ClinGen OGT (CytoSure v3) Microarray
Implementation of the DDD/ClinGen OGT (CytoSure v3) Microarray OGT UGM Birmingham 08/09/2016 Dom McMullan Birmingham Women's NHS Trust WM chromosomal microarray (CMA) testing Population of ~6 million (10%)
More informationCurrent controversies in prenatal diagnosis 3: is conventional chromosome analysis necessary in the post-array CGH era?
PRENATAL DIAGNOSIS Prenat Diagn 2011; 31: 235 243. Published online 10 February 2011 in Wiley Online Library (wileyonlinelibrary.com).2722 DEBATE Current controversies in prenatal diagnosis 3: is conventional
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationCase 1B. 46,XY,-14,+t(14;21)
Case 1B 46,XY,-14,+t(14;21) G-banded Chromosome telomere centromere G-dark bands AT-rich few genes G-pale bands GC-rich many genes telomere ideograms ideograms Conventional (light microscopy) p = short
More informationSeptember 04, 2008
27027 Tourney Road Valencia, CA 91355 800 421 7110 www.specialtylabs.com Test Updates September 04, 2008 Dear Valued Client: As you may be aware, in recent years there has been a tremendous challenge in
More informationDefining Actionable Novel Discoveries, Annotating Genomes, and Reanalysis in Cancer A Laboratory Perspective
Integrating Large-Scale Genomic Information into Clinical Practice: A Workshop Defining Actionable Novel Discoveries, Annotating Genomes, and Reanalysis in Cancer A Laboratory Perspective Federico A. Monzon
More informationCytogenetics 101: Clinical Research and Molecular Genetic Technologies
Cytogenetics 101: Clinical Research and Molecular Genetic Technologies Topics for Today s Presentation 1 Classical vs Molecular Cytogenetics 2 What acgh? 3 What is FISH? 4 What is NGS? 5 How can these
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More information22q11.2 DELETION SYNDROME. Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona)
22q11.2 DELETION SYNDROME Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona) Genomic disorders GENOMICS DISORDERS refers to those diseases
More informationGenetics Quality and Accreditation workshop Manchester 17 th May 2017
Genetics Quality and Accreditation workshop Manchester 17 th May 2017 Katrina Rack Oxford CEQAS What is CEQAS Types of schemes Scheme update Highlights 2016 Key recommendations CEQAS Background External
More informationGENOME-WIDE ANALYSIS BY SNP ARRAY
GENOME-WIDE ANALYSIS BY SNP ARRAY SNP ARRAY IN THE DIAGNOSIS OF INTELLECTUAL DISABILITY AND C O N G E N I T A L ABNORMALITIES Contents Introduction... 3 Conventional and molecular cytogenetics (FISH)...
More informationGenome-wide analysis by SNP Array
Genome-wide analysis by SNP Array SNP Array in the diagnosis of Mental Retardation and Congenital Abnormalities Contents Introduction...3 Conventional and molecular cytogenetics (FISH)...4 1. Karyotyping...4
More informationSEAMLESS CGH DIAGNOSTIC TESTING
SEAMLESS CGH DIAGNOSTIC TESTING GENETISURE DX POSTNATAL ASSAY Informed decisions start with a complete microarray platform for postnatal analysis For In Vitro Diagnostic Use INTENDED USE: GenetiSure Dx
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES COMPARATIVE GENOMIC HYBRIDIZATION (CGH) MICROARRAY TESTING FOR DEVELOPMENTAL DELAY, AUTISM SPECTRUM DISORDER AND INTELLECTUAL DISABILITY The purpose of this policy is to
More informationMLPA SAMPLES USER GUIDE
MLPA SAMPLES USER GUIDE MLPA microdeletion studies Requirements: 1-2 mls (minimum) of peripheral blood in a lithium heparin tube (green or orange top) AND 1-2 mls of peripheral blood in a EDTA tube (purple
More informationMULTIPLE CHOICE QUESTIONS
SHORT ANSWER QUESTIONS-Please type your awesome answers on a separate sheet of paper. 1. What is an X-linked inheritance pattern? Use a specific example to explain the role of the father and mother in
More informationGenetic Testing for Single-Gene and Multifactorial Conditions
Clinical Appropriateness Guidelines Genetic Testing for Single-Gene and Multifactorial Conditions EFFECTIVE MARCH 31, 2019 Appropriate.Safe.Affordable 2019 AIM Specialty Health 2069-0319 Table of Contents
More informationSection: Genetic Testing Last Reviewed Date: April Policy No: 58 Effective Date: July 1, 2014
Medical Policy Manual Topic: Genetic Testing, including Chromosomal Microarray Analysis (CMA) and Next Generation Sequencing Panels, for the Genetic Evaluation of Patients with Developmental Delay/Intellectual
More informationIntroduction to LOH and Allele Specific Copy Number User Forum
Introduction to LOH and Allele Specific Copy Number User Forum Jonathan Gerstenhaber Introduction to LOH and ASCN User Forum Contents 1. Loss of heterozygosity Analysis procedure Types of baselines 2.
More informationChapter 15 Notes 15.1: Mendelian inheritance chromosome theory of inheritance wild type 15.2: Sex-linked genes
Chapter 15 Notes The Chromosomal Basis of Inheritance Mendel s hereditary factors were genes, though this wasn t known at the time Now we know that genes are located on The location of a particular gene
More informationStructural Variation and Medical Genomics
Structural Variation and Medical Genomics Andrew King Department of Biomedical Informatics July 8, 2014 You already know about small scale genetic mutations Single nucleotide polymorphism (SNPs) Deletions,
More informationSALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B
SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B1-0613. The purpose of the P372 probemix is to further investigate results found with the P245 Microdeletion Syndromes-1A probemix. The
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationStatistical Analysis of Single Nucleotide Polymorphism Microarrays in Cancer Studies
Statistical Analysis of Single Nucleotide Polymorphism Microarrays in Cancer Studies Stanford Biostatistics Workshop Pierre Neuvial with Henrik Bengtsson and Terry Speed Department of Statistics, UC Berkeley
More informationCase Report Prenatal Diagnosis of Cystic Hygroma related to a Deletion of 16q24.1 with Haploinsufficiency of FOXF1 and FOXC2 Genes
Case Reports in Genetics Volume 2012, Article ID 490408, 4 pages doi:10.1155/2012/490408 Case Report Prenatal Diagnosis of Cystic Hygroma related to a Deletion of 16q24.1 with Haploinsufficiency of FOXF1
More informationSNP array karyotyping for clinical cancer applications
SNP array karyotyping for clinical cancer applications Jill M. Hagenkord, MD, FCAP Genomic Pathologist Chief Medical Officer Complete Genomics, Inc. Mountain View, CA Disclosures Jill Hagenkord is a co-founder
More informationGenomic structural variation
Genomic structural variation Mario Cáceres The new genomic variation DNA sequence differs across individuals much more than researchers had suspected through structural changes A huge amount of structural
More informationchromosomal anomalies and mental pdf Chapter 8: Chromosomes and Chromosomal Anomalies (PDF) Chromosomal abnormalities -A review - ResearchGate
DOWNLOAD OR READ : CHROMOSOMAL ANOMALIES AND MENTAL RETARDATION FROM GENOTYPES TO NEUROPSYCHOLOGICAL PHENOTYPES OF GENETIC SYNDROMES AT HIGH INCIDENCEGENOTYPE TO PHENOTYPE PDF EBOOK EPUB MOBI Page 1 Page
More informationSNP Arrays in Cancer Diagnostics
1 1. Introduction SNP Arrays in Cancer Diagnostics Federico A. Monzon, M.D. The Methodist Hospital Research Institute, Houston TX Detection of acquired chromosomal gains/losses in human tumors is clinically
More informationApplication of Array-based Comparative Genome Hybridization in Children with Developmental Delay or Mental Retardation
Pediatr Neonatol 2008;49(6):213 217 REVIEW ARTICLE Application of Array-based Comparative Genome Hybridization in Children with Developmental Delay or Mental Retardation Jao-Shwann Liang 1,2 *, Keiko Shimojima
More informationEvolution of Genetic Testing. Joan Pellegrino MD Associate Professor of Pediatrics SUNY Upstate Medical University
Evolution of Genetic Testing Joan Pellegrino MD Associate Professor of Pediatrics SUNY Upstate Medical University Genetic Testing Chromosomal analysis Flourescent in situ hybridization (FISH) Chromosome
More informationIntroduction to Cytogenetics
Introduction to Cytogenetics Catherine McCarthy Pathology Qld Cytogenetic abnormalities constitutional acquired: clonal: related or unrelated non-clonal Investigating constitutional abnormalities peripheral
More informationGlobal variation in copy number in the human genome
Global variation in copy number in the human genome Redon et. al. Nature 444:444-454 (2006) 12.03.2007 Tarmo Puurand Study 270 individuals (HapMap collection) Affymetrix 500K Whole Genome TilePath (WGTP)
More informationGenetic Disorders. PART ONE: Detecting Genetic Disorders. Amniocentesis Chorionic villus sampling Karyotype Triple Screen Blood Test
Genetic Disorders PART ONE: Detecting Genetic Disorders Amniocentesis Chorionic villus sampling Karyotype Triple Screen Blood Test Amniocentesis A technique for determining genetic abnormalities in a fetus
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Manchester RGC Approved: September 2013
More informationStructural Chromosome Aberrations
Structural Chromosome Aberrations 2 Structural chromosome aberrations or chromosome mutations represent apart from aneuploidies the most frequent pathologic findings in applied chromosome diagnostics.
More informationClinical Policy Title: Genetic testing for primary autosomal recessive microcephaly
Clinical Policy Title: Genetic testing for primary autosomal recessive microcephaly Clinical Policy Number: (391) 02.01.03 Effective Date: June 1, 2013 Initial Review Date: April 22, 2013 Most Recent Review
More informationCardiovascular Molecular Cytogenetics Methylenetetrahydrofolate Oligodendrogliomas Reductase (MTHFR) Mutation SS18 (C677T & A1298C) QF-PCR Sample:
Genetics Testing Dorevitch Pathology offers a comprehensive range of molecular and cytogenetic tests covering a wide spectrum of clinical indications to help in the diagnosis, management and treatment
More informationCYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING
INTRODUCTION The Cytogenetics Laboratory offers a comprehensive array of chromosome investigations for cancers, constitutional abnormalities, and prenatal and postnatal diagnosis. Analyses are performed
More information